Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for Prevention of Anthracycline Cardiotoxicity in Breast Cancer
NCT01708798Phase 3Terminated
- Sponsor
- University of British Columbia
- Start
- May 2014
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of eplerenone in anthracycline-induced cardiotoxicity, sponsored by University of British Columbia. Started May 2014; status: terminated.
02
Drugs
eplerenone
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT01708798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01708798.